Semax in Canada
Nootropic / Neuroprotective
Also known as MEHFPGP, Pro-Gly-Pro-ACTH(4-7).
Semax is not in the catalogue yet. When it ships it will be dispatched from British Columbia, so Canadian orders clear no customs and cross no border. Add your email below and you will hear the day it is available.
Notify me when Semax is available
One email when it launches. Nothing else.
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
About Semax
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from adrenocorticotropic hormone (ACTH) fragment 4-10, with an added Pro-Gly-Pro sequence for metabolic stability. Molecular weight is approximately 813.88 g/mol (formula C37H51N9O10S). Discovered in Russia during the 1980s as part of government-funded neuropeptide research, it is approved in Russia and Ukraine for the treatment of ischemic stroke, cognitive disorders, encephalopathy, and optic nerve atrophy. Despite its ACTH origin, Semax does not activate adrenal corticosteroid production, acting selectively on brain-specific pathways.
Mechanism
Semax is a brain-selective heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813.88 g/mol) that crosses the blood-brain barrier via intranasal absorption. It increases brain-derived neurotrophic factor (BDNF) expression and upregulates trkB receptors, supporting neuroplasticity and long-term memory formation. It enhances nerve growth factor (NGF) levels, modulates serotonergic and dopaminergic neurotransmission (supporting mood, motivation, and cognitive drive), supports enkephalin signaling, and reduces cortisol's harmful effects on the brain during stress. It has neuroprotective effects against oxidative stress and influences the HPA axis. Recent research shows Semax may interact with mu-opioid receptors for spinal cord injury applications (PMID: 40692165) and modulates copper-induced amyloid-beta aggregation relevant to Alzheimer's disease (PMID: 39767736). Despite its ACTH 4-10 fragment origin, the specific fragment does not activate adrenal corticosteroid production. Plasma half-life is several minutes, but pharmacological effects of a single intranasal dose at 16 mcg/kg persist for approximately 24 hours.
In the meantime
Volta Peptides supplies materials strictly for in-vitro laboratory research. Nothing on this page is a drug, supplement, cosmetic or food, and nothing here is intended for human or animal use, clinical application or diagnostic procedures. The research summary above describes published literature and is not a claim of therapeutic benefit or a statement that this compound is offered for such use.